文献速递前列腺癌

导管型前列腺癌常规治疗效果不佳

Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies.
PubMed 文献 · Eur Urol · 2020-12-03

单中心回顾性研究比较导管型前列腺腺癌(DAC)与高危前列腺腺癌(PAC)接受根治性治疗后的结局,发现DAC患者无论行根治性前列腺切除或放疗,5年无转移生存率和总生存率均显著更差,且ADT效果有限,可能与内在雄激素抵抗通路上调有关。

要点

  • DAC接受RP或RTx后5年MFS和OS均显著劣于高危PAC。
  • ADT未能改善DAC结局,且新辅助ADT未导致病理降级。
  • DAC存在内在雄激素抵抗通路上调,需探索新治疗策略。

核心结论

  • DAC患者接受RP或RTx后结局均差于PAC患者,且ADT效果有限。

研究设计与样本

  • 单中心回顾性研究纳入2005-2018年cT1-4/N0-1 DAC患者228例,其中163例行RP,34例行RTx,31例术前行新辅助治疗。
  • 分别将163例DAC与155例PAC行RP者比较,34例DAC与74例PAC行RTx者比较。

主要发现

  • RP后DAC与PAC的5年MFS分别为75% vs 95%(p < 0.001),5年OS分别为88% vs 97%(p < 0.05)。
  • RTx后DAC与PAC的5年MFS分别为62% vs 93%(p < 0.001),5年OS分别为82% vs 100%(p < 0.05)。
  • RP后接受辅助/挽救ADT的76例患者中,DAC的MFS和OS仍差于PAC(p < 0.01)。
  • 基因组分析显示10/11(91%)接受ADT的DAC存在雄激素抵抗通路内在上调。
  • 15例仅接受新辅助ADT后行RP的DAC患者均无病理降级(0/15)。

临床怎么用

  • DAC患者采用常规RP或RTx及ADT时需预期较差结局,应考虑临床试验探索新策略。

局限性

  • 回顾性研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ductal prostate adenocarcinoma (DAC) is a rare, aggressive, histologic variant of prostate cancer that is treated with conventional therapies, similar to high-risk prostate adenocarcinoma (PAC). OBJECTIVE: To assess the outcomes of men undergoing definitive therapy for DAC or high-risk PAC and to explore the effects of androgen deprivation therapy (ADT) in improving the outcomes of DAC. DESIGN, SETTING, AND PARTICIPANTS: A single-center retrospective review of all patients with cT1-4/N0-1 DAC from 2005 to 2018 was performed. Those undergoing radical prostatectomy (RP) or radiotherapy (RTx) for DAC were compared with cohorts of high-risk PAC patients. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Metastasis-free survival (MFS) and overall survival (OS) rates were analyzed using Kaplan-Meier and Cox regression models. RESULTS AND LIMITATIONS: A total of 228 men with DAC were identified; 163 underwent RP, 34 underwent RTx, and 31 had neoadjuvant therapy prior to RP. In this study, 163 DAC patients and 155 PAC patients undergoing RP were compared. Similarly, 34 DAC patients and 74 PAC patients undergoing RTx were compared. DAC patients undergoing RP or RTx had worse 5-yr MFS (75% vs 95% and 62% vs 93%, respectively, p < 0.001) and 5-yr OS (88% vs 97% and 82% vs 100%, respectively, p < 0.05) compared with PAC patients. In the 76 men who received adjuvant/salvage ADT after RP, DAC also had worse MFS and OS than PAC (p < 0.01). A genomic analysis revealed that 10/11 (91%) DACs treated with ADT had intrinsic upregulation of androgen-resistant pathways. Further, none of the DAC patients (0/15) who received only neoadjuvant ADT prior to RP had any pathologic downgrading. The retrospective nature was a limitation. CONCLUSIONS: Men undergoing RP or RTx for DAC had worse outcomes than PAC patients, regardless of the treatment modality. Upregulation of several intrinsic resistance pathways in DAC rendered ADT less effective. Further evaluation of the underlying biology of DAC with clinical trials is needed. PATIENT SUMMARY: This study demonstrated worse outcomes among patients with ductal adenocarcinoma of the prostate than among high-grade prostate adenocarcinoma patients, regardless of the treatment modality.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ranasinghe W, Shapiro DD, Hwang H, et al. Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. Eur Urol. 2020. PMID: 33279304. doi:10.1016/j.eururo.2020.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。